The Australian share market has been relatively stable, with the XJO index holding within the 8,500-point range despite recent economic pressures such as higher-than-expected CPI figures and rising bond yields. In this context, investors might find value in exploring penny stocks—an investment area that remains relevant for those interested in smaller or newer companies. These stocks can offer potential growth opportunities when supported by strong financial health, making them intriguing options for those looking to uncover promising candidates with long-term potential.
Top 10 Penny Stocks In Australia
| Name | Share Price | Market Cap | Rewards & Risks |
| Alfabs Australia (ASX:AAL) | A$0.395 | A$113.2M | ✅ 4 ⚠️ 4 View Analysis > |
| EZZ Life Science Holdings (ASX:EZZ) | A$1.515 | A$71.47M | ✅ 3 ⚠️ 2 View Analysis > |
| Dusk Group (ASX:DSK) | A$0.82 | A$51.06M | ✅ 4 ⚠️ 2 View Analysis > |
| IVE Group (ASX:IGL) | A$2.86 | A$439.55M | ✅ 4 ⚠️ 3 View Analysis > |
| MotorCycle Holdings (ASX:MTO) | A$3.55 | A$262.21M | ✅ 4 ⚠️ 1 View Analysis > |
| Veris (ASX:VRS) | A$0.07 | A$36.87M | ✅ 3 ⚠️ 2 View Analysis > |
| West African Resources (ASX:WAF) | A$2.97 | A$3.39B | ✅ 4 ⚠️ 2 View Analysis > |
| Service Stream (ASX:SSM) | A$2.27 | A$1.39B | ✅ 3 ⚠️ 2 View Analysis > |
| MaxiPARTS (ASX:MXI) | A$2.40 | A$133.31M | ✅ 3 ⚠️ 2 View Analysis > |
| GWA Group (ASX:GWA) | A$2.49 | A$653.07M | ✅ 5 ⚠️ 1 View Analysis > |
Click here to see the full list of 412 stocks from our ASX Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Beacon Minerals (ASX:BCN)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Beacon Minerals Limited, along with its subsidiaries, focuses on the development and production of minerals in Western Australia and has a market capitalization of A$281.57 million.
Operations: The company's revenue is derived entirely from the exploration and development of minerals, amounting to A$92.73 million.
Market Cap: A$281.57M
Beacon Minerals Limited, with a market cap of A$281.57 million, focuses on mineral development and production in Western Australia. Despite being currently unprofitable and experiencing a 48.6% annual decline in earnings over five years, the company has managed to reduce its debt-to-equity ratio significantly from 49.3% to 12.5%. Its short-term assets exceed both short- and long-term liabilities, indicating strong liquidity management. Recent announcements include a fully franked ordinary dividend of A$0.04 and a special dividend of A$0.01, reflecting some level of shareholder returns amid operational challenges in profitability and growth acceleration.
- Click here and access our complete financial health analysis report to understand the dynamics of Beacon Minerals.
- Explore historical data to track Beacon Minerals' performance over time in our past results report.
Botanix Pharmaceuticals (ASX:BOT)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Botanix Pharmaceuticals Limited is a commercial dermatology company operating in Australia and the United States with a market cap of A$246.33 million.
Operations: The company's revenue is primarily derived from its Research and Development Dermatology and Antimicrobial Products segment, which generated A$5.79 million.
Market Cap: A$246.33M
Botanix Pharmaceuticals Limited, a commercial dermatology company with a market cap of A$246.33 million, is currently pre-revenue with limited revenue from its R&D Dermatology and Antimicrobial Products segment (A$5.79 million). The company has no debt and short-term assets of A$99.6 million that exceed both short- and long-term liabilities, suggesting solid liquidity. Despite being unprofitable with increasing losses over five years, Botanix is trading at 80% below estimated fair value and forecasts suggest significant earnings growth potential at 84.19% annually. Recent developments include executive changes and updates on Sofdra® gel launch momentum.
- Get an in-depth perspective on Botanix Pharmaceuticals' performance by reading our balance sheet health report here.
- Review our growth performance report to gain insights into Botanix Pharmaceuticals' future.
Oneview Healthcare (ASX:ONE)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Oneview Healthcare PLC develops and sells software services for the healthcare sector across several regions including Ireland, the United States, Australia, the Middle East, and Asia, with a market cap of A$257.02 million.
Operations: The company's revenue is primarily derived from its Patient Engagement Solution for the Healthcare Sector, amounting to €11.57 million.
Market Cap: A$257.02M
Oneview Healthcare PLC, with a market cap of A$257.02 million, derives its revenue primarily from its Patient Engagement Solution, totaling €11.57 million. The company remains unprofitable and is not expected to achieve profitability in the next three years. Despite this, Oneview has no debt and short-term assets exceeding both short- and long-term liabilities, indicating a stable financial position. Recent board changes include the appointment of Michael J. Dowling as a Non-Executive Director, bringing extensive healthcare leadership experience that could aid in scaling their digital platform globally amidst forecasted revenue growth of 26.39% annually.
- Click here to discover the nuances of Oneview Healthcare with our detailed analytical financial health report.
- Examine Oneview Healthcare's earnings growth report to understand how analysts expect it to perform.
Make It Happen
- Reveal the 412 hidden gems among our ASX Penny Stocks screener with a single click here.
- Contemplating Other Strategies? Rare earth metals are the new gold rush. Find out which 37 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Beacon Minerals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com